Although this study still has some drawbacks such as the limited number of clinical specimens and plain mechanism research, all the characteristics and functions of PSMA make it a fairly promising therapeutic target for anti-angiogenesis therapy of GBM. The gene discussed is FOLH1; the disease is glioblastoma.